Phase I/II trial of capecitabine plus irinotecan for metastatic breast cancer patient who pretreated with anthracycline and taxane agents

Phase I/II trial of capecitabine plus irinotecan for metastatic breast cancer patient who pretreated with anthracycline and taxane agents - CAPIRI-Breast

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001531

Enrollment

Registered

2008-12-01

Start date

2005-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic breast cancer

Interventions

Capecitabine plus irinotecan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)metastatic breast cancer 2)patient who had received both anthracycline and taxane agents

Exclusion criteria

Exclusion criteria: 1)Patient have no indication of chemotherapy 2)patient who have priortreated with capecitabine or irinotecan

Design outcomes

Primary

Measure	Time frame
Response rate	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026